DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq

Core Viewpoint - DBV Technologies has announced the sale of approximately $30 million of American Depositary Shares (ADSs) through its At-The-Market (ATM) program on Nasdaq, aimed at raising funds for its clinical-stage biopharmaceutical operations [1][2]. Group 1: Financial Details - The company will issue 11,538,460 new Ordinary Shares, equivalent to 2,307,692 new ADSs, at an at-the-market price of $13.00 per ADS, resulting in gross proceeds of approximately $30 million before expenses [2]. - The issuance price per Ordinary Share is €2.2264, based on the USD/EUR exchange rate of $1.1678 for €1, reflecting a discount of 3.41% to the last closing price on Euronext Paris [2]. - The new Ordinary Shares will represent 8.42% of the existing shares on Euronext Paris, with a dilution effect of approximately 7.77% upon completion of the transaction [3][4]. Group 2: Regulatory and Market Information - The new ADSs will be admitted to trading on Nasdaq, while the new Ordinary Shares will be listed on Euronext Paris [3]. - The share capital increase is exempt from the requirement of a prospectus approval by the French Financial Markets Authority, as it is offered to qualified investors and represents less than 30% of the existing shares over a rolling 12-month period [6][12]. Group 3: Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immunologic conditions, utilizing its proprietary Viaskin technology platform [12][13]. - The company is currently conducting clinical trials for its Viaskin Peanut product aimed at treating peanut allergies in young children [12].